Merck to acquire Prometheus in a US$ 10.8 b deal, page-93

As evidence, he points to the acquisition of neurological therapy business Reata Pharmaceuticals by Biogen for $US7.3 billion ($11.2 billion) in July 2023.By comparison, Neuren had a market value of $2.9 billion on February 12 and De Silva says Reata’s lead drug, Skyclarys, treats a condition two-and-a-half times less prevalent than Rett syndrome.

Daybue is exceeding forecasts for initial adoption and patients are tolerating the treatment regimen above expectations,” says Smith. “More excitingly, the next drug [at the clinical trial stage] has produced positive topline results with the phase 2 trial.”Hashan De Silva, founder and managing partner at medtech investment fund KP Rx, reckons Neuren’s success makes it a takeover target for big pharma. De Silva formerly worked as a healthcare analyst at broker CLSA and hedge fund Karst Peak.

Neuren: Sophie Smith, an investment analyst for the SGH Medical Technology Fund, believes the biotech company will continue its stunning rise – 1609 per cent higher over the past five years. Neuren has commercialised a drug named Daybue to treat neurological disorder Rett syndrome in children and has other drugs in clinical trials.